MA50247B1 - Compositions aqueuses comprenant de la bilastine et du mométasone - Google Patents
Compositions aqueuses comprenant de la bilastine et du mométasoneInfo
- Publication number
- MA50247B1 MA50247B1 MA50247A MA50247A MA50247B1 MA 50247 B1 MA50247 B1 MA 50247B1 MA 50247 A MA50247 A MA 50247A MA 50247 A MA50247 A MA 50247A MA 50247 B1 MA50247 B1 MA 50247B1
- Authority
- MA
- Morocco
- Prior art keywords
- bilastine
- mometasone
- pharmaceutical composition
- relates
- aqueous pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382686 | 2017-10-16 | ||
| PCT/EP2018/078034 WO2019076798A1 (en) | 2017-10-16 | 2018-10-15 | AQUEOUS COMPOSITIONS COMPRISING BILASTIN AND MOMETASONE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50247A MA50247A (fr) | 2020-07-22 |
| MA50247B1 true MA50247B1 (fr) | 2021-02-26 |
Family
ID=60262869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50247A MA50247B1 (fr) | 2017-10-16 | 2018-10-15 | Compositions aqueuses comprenant de la bilastine et du mométasone |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11642309B2 (enExample) |
| EP (1) | EP3681475B1 (enExample) |
| JP (1) | JP2020536972A (enExample) |
| KR (1) | KR20200125923A (enExample) |
| CN (1) | CN111526869A (enExample) |
| AU (1) | AU2018353360B2 (enExample) |
| BR (1) | BR112020007569A2 (enExample) |
| CA (1) | CA3079303A1 (enExample) |
| CO (1) | CO2020005939A2 (enExample) |
| DK (1) | DK3681475T3 (enExample) |
| EA (1) | EA202090965A1 (enExample) |
| ES (1) | ES2858573T3 (enExample) |
| HR (1) | HRP20210260T1 (enExample) |
| HU (1) | HUE053233T2 (enExample) |
| IL (1) | IL273967A (enExample) |
| LT (1) | LT3681475T (enExample) |
| MA (1) | MA50247B1 (enExample) |
| MX (1) | MX2020003834A (enExample) |
| PL (1) | PL3681475T3 (enExample) |
| PT (1) | PT3681475T (enExample) |
| SG (1) | SG11202003384XA (enExample) |
| TW (1) | TW201922250A (enExample) |
| WO (1) | WO2019076798A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201918617D0 (en) * | 2019-12-17 | 2020-01-29 | Reckitt Benckiser Health Ltd | Personal lubricant composition |
| CN116211795B (zh) * | 2022-12-26 | 2025-09-26 | 深圳市贝美药业有限公司 | 一种比拉斯汀口服液体制剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2048109B1 (es) | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| DE4426709A1 (de) | 1994-07-20 | 1996-01-25 | Schering Ag | Steroidale Sexualhormone enthaltende feste Arzneiformen |
| ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| FR2780901B1 (fr) * | 1998-07-09 | 2000-09-29 | Coletica | Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant |
| GB0312148D0 (en) * | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
| US20060045850A1 (en) | 2004-08-30 | 2006-03-02 | Qpharma, Llc | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
| EP1896086A1 (en) | 2005-06-30 | 2008-03-12 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
| US20070082870A1 (en) | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| EP1894559A1 (en) | 2006-09-01 | 2008-03-05 | PARI Pharma GmbH | Means to solubilise steroids for inhalation |
| CN101273993A (zh) * | 2007-03-27 | 2008-10-01 | 北京亚欣保诚医药科技有限公司 | 糠酸莫米松溶液型液体制剂 |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| CN101795565A (zh) * | 2007-06-28 | 2010-08-04 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
| CN101756998A (zh) * | 2008-11-28 | 2010-06-30 | 天津金耀集团有限公司 | 采用环糊精包合糠酸莫米松的鼻用药物组合物 |
| CN201373609Y (zh) | 2009-03-13 | 2009-12-30 | 潘戈 | 太阳能集热器箱体 |
| EP2437743A4 (en) | 2009-06-05 | 2012-11-28 | Aciex Therapeutics Inc | OPHTHALMIC FORMULATIONS OF FLUTICASONE AND METHODS OF USE |
| KR101304341B1 (ko) | 2011-09-19 | 2013-09-11 | 한미약품 주식회사 | 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물 |
| US9629847B2 (en) | 2011-11-23 | 2017-04-25 | Michael Leighton | Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant |
| CN103736098A (zh) * | 2013-12-27 | 2014-04-23 | 于运红 | 一种含有比拉斯汀及糠酸莫米松的鼻内给药用药物组合物 |
| CN103784462A (zh) * | 2014-02-25 | 2014-05-14 | 宋俊智 | 包含比拉斯汀及甾族化合物的药物制剂 |
| EP3040334A1 (en) * | 2014-12-29 | 2016-07-06 | Faes Farma, S.A. | New benzimidazole derivatives as antihistamine agents |
| WO2016141219A1 (en) | 2015-03-05 | 2016-09-09 | Cosmederm Bioscience, Inc. | Strontium based compositions and formulations for pain, pruritus, and inflammation |
| WO2017008265A1 (en) * | 2015-07-15 | 2017-01-19 | Abb Technology Ag | Conductive bar with annular portion to accommodate test plug |
| EP3170816A1 (en) * | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Supersaturated compositions of benzimidazole compounds |
-
2018
- 2018-10-15 BR BR112020007569-8A patent/BR112020007569A2/pt not_active Application Discontinuation
- 2018-10-15 JP JP2020542191A patent/JP2020536972A/ja active Pending
- 2018-10-15 US US16/756,112 patent/US11642309B2/en active Active
- 2018-10-15 EA EA202090965A patent/EA202090965A1/ru unknown
- 2018-10-15 PL PL18786334T patent/PL3681475T3/pl unknown
- 2018-10-15 KR KR1020207013961A patent/KR20200125923A/ko not_active Ceased
- 2018-10-15 WO PCT/EP2018/078034 patent/WO2019076798A1/en not_active Ceased
- 2018-10-15 CN CN201880080642.3A patent/CN111526869A/zh active Pending
- 2018-10-15 AU AU2018353360A patent/AU2018353360B2/en not_active Ceased
- 2018-10-15 HR HRP20210260TT patent/HRP20210260T1/hr unknown
- 2018-10-15 MA MA50247A patent/MA50247B1/fr unknown
- 2018-10-15 PT PT187863345T patent/PT3681475T/pt unknown
- 2018-10-15 EP EP18786334.5A patent/EP3681475B1/en active Active
- 2018-10-15 DK DK18786334.5T patent/DK3681475T3/da active
- 2018-10-15 ES ES18786334T patent/ES2858573T3/es active Active
- 2018-10-15 CA CA3079303A patent/CA3079303A1/en not_active Abandoned
- 2018-10-15 HU HUE18786334A patent/HUE053233T2/hu unknown
- 2018-10-15 SG SG11202003384XA patent/SG11202003384XA/en unknown
- 2018-10-15 LT LTEP18786334.5T patent/LT3681475T/lt unknown
- 2018-10-15 MX MX2020003834A patent/MX2020003834A/es unknown
- 2018-10-16 TW TW107136388A patent/TW201922250A/zh unknown
-
2020
- 2020-04-13 IL IL273967A patent/IL273967A/en unknown
- 2020-05-15 CO CONC2020/0005939A patent/CO2020005939A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3681475A1 (en) | 2020-07-22 |
| SG11202003384XA (en) | 2020-05-28 |
| EP3681475B1 (en) | 2020-12-09 |
| TW201922250A (zh) | 2019-06-16 |
| AU2018353360B2 (en) | 2021-04-01 |
| LT3681475T (lt) | 2021-02-25 |
| KR20200125923A (ko) | 2020-11-05 |
| ES2858573T3 (es) | 2021-09-30 |
| MA50247A (fr) | 2020-07-22 |
| US20210186869A1 (en) | 2021-06-24 |
| AU2018353360A1 (en) | 2020-05-07 |
| CN111526869A (zh) | 2020-08-11 |
| US11642309B2 (en) | 2023-05-09 |
| WO2019076798A1 (en) | 2019-04-25 |
| HUE053233T2 (hu) | 2021-06-28 |
| CO2020005939A2 (es) | 2020-10-30 |
| DK3681475T3 (da) | 2021-02-01 |
| CA3079303A1 (en) | 2019-04-25 |
| IL273967A (en) | 2020-05-31 |
| JP2020536972A (ja) | 2020-12-17 |
| PL3681475T3 (pl) | 2021-07-05 |
| MX2020003834A (es) | 2020-08-06 |
| HRP20210260T1 (hr) | 2021-04-02 |
| EA202090965A1 (ru) | 2020-07-22 |
| PT3681475T (pt) | 2021-03-08 |
| BR112020007569A2 (pt) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aapro | 5-HT3 receptor antagonists: an overview of their present status and future potential in cancer therapy-induced emesis | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MA41932B1 (fr) | Méthodes de traitement ou de prévention de migraines | |
| MA42292A (fr) | Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA41496B1 (fr) | Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| SA520412443B1 (ar) | تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA46268A (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| MX2021012684A (es) | Composiciones farmaceuticas estables y conservadas de bilastina. | |
| BR112023025599A2 (pt) | Ativadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA50247B1 (fr) | Compositions aqueuses comprenant de la bilastine et du mométasone | |
| MA49673B1 (fr) | Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer | |
| MA44079B1 (fr) | Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| CA3086301C (en) | PENTOSANNE POLYSULFATE AND MEDICINE CONTAINING PENTOSANNE POLYSULFATE | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| Kampf et al. | Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability | |
| CA3156182A1 (en) | METHODS FOR PROCESSING S1P1 RECEIVER BOUND STATES |